Tango Therapeutics (TNGX) had the highest return in March 2026 by a mid-cap US stock, returning 93.5%.

ASSET	MONTH	% RETURN
Tango Therapeutics (TNGX)	March 2026	93.52%
Uniqure (QURE)	March 2026	77.91%
Babcock & Wilcox Enterprises (BW)	March 2026	72.22%
Amprius Technologies (AMPX)	March 2026	61.8%
BitVentures (BVC)	March 2026	58.91%
Dianthus Therapeutics (DNTH)	March 2026	55.87%
Firefly Aerospace Inc Common Stock (FLY)	March 2026	53.89%
Avis Budget (CAR)	March 2026	53.53%
Centessa Pharmaceuticals PLC ADR (CNTA)	March 2026	49.27%
Oruka Therapeutics (ORKA)	March 2026	49.18%
Kodiak Sciences (KOD)	March 2026	45.94%
P3 Health Partners (PIII)	March 2026	44.6%
SolarEdge Technologies (SEDG)	March 2026	43.8%
Hims Hers Health (HIMS)	March 2026	43.07%
Par Pacific (PARR)	March 2026	41.02%
Sasol (SSL)	March 2026	38.76%
Navan, Inc Class A Common Stock (NAVN)	March 2026	37.63%
Xenon Pharmaceuticals (XENE)	March 2026	36.6%
AXT (AXTI)	March 2026	36.54%
Telix Pharmaceuticals (TLX)	March 2026	35.94%
Enliven Therapeutics (ELVN)	March 2026	35.92%
Celanese (CE)	March 2026	35.58%
Veradermics (MANE)	March 2026	34.39%
Atlas Energy Solutions (AESI)	March 2026	33.6%
Figure Technology Solutions, Inc Class A Common Stock (FIGR)	March 2026	33.14%

Mid-cap stocks are treated as having a market cap between $2B and $10B.